诊断学理论与实践››2019,Vol. 18››Issue (2): 218-222.doi:10.16150/j.1671-2870.2019.02.019
康凯1, 曹久妹1(
)
收稿日期:2018-12-28出版日期:2019-04-25发布日期:2019-04-25通讯作者:曹久妹 E-mail:cjm11261@rjh.com.cn基金资助:
Received:2018-12-28Online:2019-04-25Published:2019-04-25| [1] | Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxa-ban-Metabolism, Pharmacologic Properties and Drug Interactions[J]. Curr Drug Metab, 2017, 18(7):636-642. |
| [2] | Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361(12):1139-1151. |
| [3] | Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)[J]. Circulation, 2014, 130(2):138-146. |
| [4] | Chan YH, See LC, Tu HT, et al. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation[J]. J Am Heart Assoc, 2018, 7(8):e008150. |
| [5] | Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2013, 44(3):870-947. |
| [6] | Song Z, Wu H, Cao H, et al. Routine coagulation test abnormalities caused by rivaroxaban: A case report[J]. Medicine (Baltimore), 2018, 97(45):e13104. |
| [7] | Weitz JI, Eikelboom JW. Urgent Need to Measure Effects of Direct Oral Anticoagulants[J]. Circulation, 2016, 134(3):186-188. |
| [8] | Reiffel JA, Weitz JI, Reilly P, et al. NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank[J]. Am Heart J, 2016, 177:74-86. |
| [9] | Brown KS, Zahir H, Grosso MA, et al. Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal[J]. Crit Care, 2016, 20(1):273. |
| [10] | Bonar R, Favaloro EJ, Mohammed S, et al. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples[J]. Pathology, 2016, 48(1):60-71. |
| [11] | Testa S, Legnani C, Tripodi A, et al. Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study[J]. J Thromb Haemost, 2016, 14(11):2194-2201. |
| [12] | Douxfils J, Tamigniau A, Chatelain B, et al. Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays[J]. Thromb J, 2014, 12:24. |
| [13] | Henskens YMC, Gulpen AJW, van Oerle R, et al. Detecting clinically relevant rivaroxaban or dabigatran leve-ls by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation[J]. Thromb J, 2018, 16:3. |
| [14] | Samuelson BT, Cuker A. Measurement and reversal of the direct oral anticoagulants[J]. Blood Rev, 2017, 31(1):77-84. |
| [15] | Shimomura D, Nakagawa Y, Kondo H, et al. The Influe-nce of Assay Selection on Prothrombin Time Measured in Patients Treated With Rivaroxaban for Nonvalvular Atrial Fibrillation[J]. J Clin Lab Anal, 2016, 30(6):941-946. |
| [16] | Rathbun S, Tafur A, Grant R, et al. Comparison of metho-ds to determine rivaroxaban anti-factor Xa activity[J]. Thromb Res, 2015, 135(2):394-397. |
| [17] | Chan NC, Bhagirath V, Dale BJ, et al. Evaluating coagulation tests in patients with atrial fibrillation using direct oral anticoagulants[J]. Expert Rev Cardiovasc Ther, 2015, 13(11):1213-1223. |
| [18] | Samuelson BT, Cuker A, Siegal DM, et al. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review[J]. Chest, 2017, 151(1):127-138. |
| [19] | Gosselin RC, Adcock DM. The laboratory's 2015 perspective on direct oral anticoagulant testing[J]. J Thromb Haemost, 2016, 14(5):886-893. |
| [20] | Vanden Daelen S, Peetermans M, Vanassche T, et al. Monitoring and reversal strategies for new oral anticoagulants[J]. Expert Rev Cardiovasc Ther, 2015, 13(1):95-103. |
| [21] | Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report[J]. Chest, 2018, 154(5):1121-1201. |
| [22] | Cuker A, Siegal DM, Crowther MA, et al. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants[J]. J Am Coll Cardiol, 2014, 64(11):1128-1139. |
| [23] | 王哲, 谢秋芬, 向倩, 等. 直接口服抗凝药患者实验室检测的研究现状[J]. 中国临床药理学杂志, 2018, 34(10):1253-1256. |
| [24] | Colombini MP, Derogis PBMC, de Aranda VF, et al. Comparison of different laboratory tests in the evaluation of hemorrhagic risk of patients using rivaroxaban in the critical care setting: diagnostic accuracy study[J]. Thromb J, 2017, 15:21. |
| [25] | Bliden KP, Chaudhary R, Mohammed N, et al. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system[J]. J Thromb Thrombolysis, 2017, 43(4):437-445. |
| [26] | Seyve L, Richarme C, Polack B, et al. Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM)[J]. Int J Lab Hematol, 2018, 40(1):84-93. |
| [27] | Rohde G. Determination of rivaroxabana novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2008, 872(1-2):43-50. |
| [28] | Lindahl S, Dyrkorn R, Spigset O, et al. Quantification of Apixaban, Dabigatran, Edoxaban and Rivaroxaban in Human Serum by UHPLC-MS/MS-Method Development, Validation, and Application[J]. Ther Drug Monit, 2018, 40(3):369-376. |
| [29] | Billoir P, Barbay V, Joly LM, et al. Anti-Xa Oral Anticoa-gulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator[J]. Ann Pharmacother, 2019, 53(4):341-347. |
| [30] | Gosselin RC, Francart SJ, Hawes EM, et al. Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?[J]. Ann Pharmacother, 2015, 49(7):777-783. |
| [31] | Beyer J, Trujillo T, Fisher S, et al. Evaluation of a Hepa-rin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors[J]. Clin Appl Thromb Hemost, 2016, 22(5):423-428. |
| [1] | 王鸿利,.重视贫血的实验诊断和鉴别诊断[J]. 诊断学理论与实践, 2014, 13(06): 557-560. |
| [2] | 万颖蕾, 陈长强, 梁璆荔, 顾志冬,.二例H7N9禽流感病毒感染患者实验室检测分析报告[J]. 诊断学理论与实践, 2014, 13(05): 542-546. |
| [3] | 熊立凡, 姚依婷, 王鸿利,.解读血管性血友病的诊断指南[J]. 诊断学理论与实践, 2012, 11(01): 25-29. |
| [4] | 王鸿利,.血栓与止血检测在出血病和易栓症中的应用[J]. 诊断学理论与实践, 2007, 6(04): 391-395. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
